EA201592298A1 - Полуживая вирусная вакцина против респираторно-синцитиального вируса - Google Patents

Полуживая вирусная вакцина против респираторно-синцитиального вируса

Info

Publication number
EA201592298A1
EA201592298A1 EA201592298A EA201592298A EA201592298A1 EA 201592298 A1 EA201592298 A1 EA 201592298A1 EA 201592298 A EA201592298 A EA 201592298A EA 201592298 A EA201592298 A EA 201592298A EA 201592298 A1 EA201592298 A1 EA 201592298A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rsv
vaccine against
viral vaccine
sev
human viral
Prior art date
Application number
EA201592298A
Other languages
English (en)
Inventor
Мариан Виганд
Кристин Кауфманн
Original Assignee
Амвак Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амвак Аг filed Critical Амвак Аг
Publication of EA201592298A1 publication Critical patent/EA201592298A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18862—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к полуживой вакцине против респираторно-синцитиального вируса (RSV), которая содержит вектор на основе вируса Сендай (SeV) с дефектом репликации генома, экспрессирующий химерный белок F RSV/SeV. Более того, настоящее изобретение относится к способу получения вектора SeV с дефектом репликации генома по настоящему изобретению и к применению его для лечения инфекций RSV и обусловленных инфекцией RSV заболеваний.
EA201592298A 2013-06-10 2014-06-10 Полуживая вирусная вакцина против респираторно-синцитиального вируса EA201592298A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13002973 2013-06-10
PCT/EP2014/001575 WO2014198407A1 (en) 2013-06-10 2014-06-10 Semi-live respiratory syncytial virus vaccine

Publications (1)

Publication Number Publication Date
EA201592298A1 true EA201592298A1 (ru) 2016-06-30

Family

ID=48578771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592298A EA201592298A1 (ru) 2013-06-10 2014-06-10 Полуживая вирусная вакцина против респираторно-синцитиального вируса

Country Status (12)

Country Link
US (1) US20160120974A1 (ru)
EP (1) EP3008190A1 (ru)
JP (1) JP2016521566A (ru)
KR (1) KR20160025553A (ru)
CN (1) CN105378090B (ru)
AU (1) AU2014280545A1 (ru)
BR (1) BR112015030697A2 (ru)
CA (1) CA2914821A1 (ru)
EA (1) EA201592298A1 (ru)
HK (1) HK1223644A1 (ru)
MX (1) MX367093B (ru)
WO (1) WO2014198407A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
EP3309251A4 (en) * 2015-06-12 2019-03-13 Mie University VIRAL VECTOR OF PARAINFLUENZA TYPE 2 HUMAN AND VACCINE
CN106362144B (zh) * 2016-10-31 2021-02-09 武汉三利生物技术有限公司 呼吸道合胞病毒疫苗
KR20220164642A (ko) 2021-06-05 2022-12-13 이민욱 즉석 라면 조리기
WO2023227758A1 (en) * 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies

Also Published As

Publication number Publication date
CN105378090B (zh) 2020-07-10
MX367093B (es) 2019-08-05
MX2015016882A (es) 2016-10-03
HK1223644A1 (zh) 2017-08-04
EP3008190A1 (en) 2016-04-20
WO2014198407A1 (en) 2014-12-18
CA2914821A1 (en) 2014-12-18
BR112015030697A2 (pt) 2017-08-22
JP2016521566A (ja) 2016-07-25
KR20160025553A (ko) 2016-03-08
CN105378090A (zh) 2016-03-02
AU2014280545A1 (en) 2015-12-24
US20160120974A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
JOP20200091A1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
PH12018500856A1 (en) Respiratory syncytial virus vaccine
EA201790630A1 (ru) Способы получения рибозидов
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
BR112014007616A2 (pt) vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório
NZ630649A (en) Vaccine against rsv
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
EA201692034A1 (ru) Новые макроциклические соединения
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
WO2018118754A8 (en) Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
EA201592299A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201792282A1 (ru) Способы лечения заболеваний
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
TH168570B (th) วิธีการของการเตรียมนิวคลิโอไทด์อนาล็อกที่ถูกแทนที่
TH1501005414A (th) แอนติบอดีของมนุษย์ต่อเรสไพราทอรีซินไซเทียลไวรัส f โปรตีน และวิธีการใช้ของมัน
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
EA202091619A3 (ru) Антитела против tigit
AR095501A1 (es) Vacunas rsv